Sign In
Buy LMLLF
$0.0037
+0 (+0%)
At Close: Jun 22, 2026
PharmaDrug Inc. Enters Definitive Agreement to Acquire SecureDose Synthetics
07:30am, Friday, 27'th Oct 2023
Toronto, Ontario--(Newsfile Corp. - October 27, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLD) ("PharmaDrug" or the "Company"), is pleased to announce that it has entered into a definitive agre
PharmaDrug to consolidate shares, appoints new CFO
07:41am, Monday, 23'rd Oct 2023
PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) (PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF), PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF)). said it will consolidate its common shares on a seven-to-one basis from Octobe
PharmaDrug consolidates shares, appoints new CFO
07:32am, Monday, 23'rd Oct 2023
PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF). said it will consolidate its common shares on a seven-to-one basis from October 24, 2023, and that the record date for the consolidation will be October 25, 20
PharmaDrug Announces Share Consolidation and Change to Chief Financial Officer
02:03pm, Friday, 20'th Oct 2023
Toronto, Ontario--(Newsfile Corp. - October 20, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), announced today that it will be proceeding with the consolidation of
PharmaDrug Announces Amendment to Shareholder Meeting Matter
04:05pm, Tuesday, 19'th Sep 2023
Toronto, Ontario--(Newsfile Corp. - September 19, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), announced today that, further to its press release dated September
PharmaDrug advances investigational cancer therapeutic PD-001 toward in human safety trials
08:56am, Thursday, 14'th Sep 2023
PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) said it continues to advance its patented reformulated enteric-coated version of orally bioavailable cepharanthine (PD-001) as a potential treatment for oncology
PharmaDrug appoints Robert Steen as CEO and chairman
10:01am, Wednesday, 06'th Sep 2023
PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) announced it has appointed seasoned entrepreneur Robert Steen as its new CEO and chairman of the Board of Directors. Steen will succeed Daniel Cohen, who will co
PharmaDrug announces $300,000 strategic investment in Sairiyo subsidiary by PharmaTher
08:33am, Tuesday, 18'th Jul 2023
PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) has announced a $300,000 investment in its Sairiyo Therapeutics biotech subsidiary by PharmaTher Inc, a wholly-owned unit of PharmaTher Holdings. Under the agre
PharmaDrug brings on veteran consultant to maximize cepharanthine and DMT program value
08:56am, Tuesday, 23'rd May 2023
PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) announced the addition of David Posner to its advisory committee and as a consultant with a mandate for strategic initiatives and corporate restructuring. The co
PharmaDrug partners with PharmaTher to develop DMT transdermal patch technology
08:46am, Wednesday, 22'nd Feb 2023
PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) announced that it has entered into a research collaboration agreement with PharmaTher Holdings Ltd to evaluate the delivery of N,N-Dimethyltryptamine (DMT) using
PharmaDrug unveils plans for first-in-human clinical study with its lead drug candidate PD-001 in esophageal cancer
09:11am, Monday, 13'th Feb 2023
PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) revealed that it intends to pursue a first-in-human study of its lead drug candidate cepharanthine-2HCL (PD-001) for oral administration, in Australia during the
PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) has filed a patent cooperation treaty (PCT) application for its lead drug cepharanthine-2HCL (PD-001) for the treatment of prostate cancer. Filing a PCT gives th
PharmaDrug wraps up key step in production of oral bioavailable version of its oncology and infectious disease drug cepharanthine
09:58am, Tuesday, 04'th Oct 2022
PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) has announced the completion of cGMP (good manufacturing practices) production of a multi-kilogram batch of cepharanthine-2HCl, a key ingredient in PD-001, the o
PharmaDrug aims to file provisional patent for treatment of glaucoma in the fourth quarter this year
10:18am, Thursday, 25'th Aug 2022
PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) told investors it continues to advance its psychedelics research and development (R&D) strategy and aims to file a provisional patent describing novel therapeuti
PharmaDrug completes significant groundwork to support multi-kilogram production of cepharanthine-2HCL drug
09:41am, Friday, 19'th Aug 2022
PharmaDrug Inc said it has completed significant groundwork to support multi-kilogram production for use in the final drug production of PD-001, its patented, oral version of cepharanthine, to treat
